Levodopa/benserazide
| Combination of | |
|---|---|
| Levodopa | Dopamine agonist |
| Benserazide | Decarboxylase inhibitor |
| Names | |
| Trade names | Prolopa, Madopar, others[1] |
| Other names | Co-beneldopa[2] |
| Clinical data | |
| Main uses | Parkinson disease[2] |
| Side effects | Anxiety, depression, heart arrhythmias, hallucinations, low blood pressure with standing, loss of appetite, impulse control disorders, sudden sleepiness[2] |
| Pregnancy category |
|
| Routes of use | By mouth |
| Legal | |
| Legal status | |
Levodopa/benserazide, also known as co-beneldopa and sold under the brand name Prolopa among others, is a combination medication used to treat Parkinson disease.[4][2] It is taken by mouth.[4]
Common side effects include anxiety, depression, heart arrhythmias, hallucinations, low blood pressure with standing, and loss of appetite.[2] Other side effects can include impulse control disorders and sudden sleepiness.[2] It is not recommended in those with severe liver problems.[2] Stopping suddenly may result in severe muscle breakdown.[2] It is composed of levodopa, a dopamine agonist and benserazide, a decarboxylase inhibitor.[2]
The combination was approved for medical use in Canada in 1977.[4] It is on the World Health Organization's List of Essential Medicines as an alternative to levodopa/carbidopa.[6] In the United Kingdom a 100 tablets costs the NHS about £10 as of 2023.[7]
Medical uses
Levodopa/benserazide is indicated for the treatment of Parkinson's disease with the exception of drug-induced parkinsonism.[3][4][5]
Dosage
The dose is based on the levodopa and range from 50 mg once per day to up to 800 mg in divided doses.[2]
References
- ↑ "Levodopa". Archived from the original on 2023-02-28. Retrieved 2023-02-23.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 "Co-beneldopa". BNF. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- ↑ 3.0 3.1 3.2 "Archive copy". Archived from the original on 2023-01-09. Retrieved 2023-02-23.
{{cite web}}: CS1 maint: archived copy as title (link) - ↑ 4.0 4.1 4.2 4.3 4.4 "Prolopa Product information". Health Canada. 25 April 2012. Archived from the original on 2 March 2023. Retrieved 8 January 2023.
- ↑ 5.0 5.1 "Madopar 100 mg/25 mg Dispersible Tablets - Summary of Product Characteristics (SmPC)". (emc). 8 April 2020. Archived from the original on 28 February 2023. Retrieved 9 January 2023.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ "Co-beneldopa Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
External links
| Identifiers: |
|---|
 | This pharmacology-related article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- CS1 maint: archived copy as title
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Antiparkinsonian agents
- Aromatic L-amino acid decarboxylase inhibitors
- Hydrazides
- Peripherally selective drugs
- Pyrogallols
- World Health Organization essential medicines (alternatives)
- RTT
- All stub articles
- Pharmacology stubs